Adapt and test the effectiveness of MBRP for substance use peer workers compared to a standard of care (referral to 12-step) control condition on substance use, relapse risk, and burnout among peers in a pilot hybrid type 1 trial. The goal of this clinical trial is to learn if Mindfulness-Based Relapse Prevention can reduce substance use, relapse risk, and burnout among substance use peer workers. The objectives are to: 1. Identify the causes, consequences, and risk and protective factors for relapse among peer workers; 2. Identify peers' preferences related to MBRP content, structure, and delivery; 3. Adapt the MBRP intervention for peer workers; and 4. Assess the preliminary effectiveness and implementation outcomes of the adapted MBRP intervention. Researchers will compare MBRP to referral to 12-step (standard of care) to see if MRBP works to reduce substance use, relapse risk, and burnout. Participants will asked to: * Participate in MBRP (8 weekly 2-hour virtual sessions) * Complete 4 surveys assessing well-being outcomes * Participate in 1 virtual interview about your experience
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from baseline in biologically verified substance use at 1, 3, and 6 months as measured by Saliva Drug Assays
Timeframe: From enrollment to 6 months
Change from baseline in self-reported substance use days at 1, 3, and 6 months as measured by the Timeline Follow-Back (TLFB)
Timeframe: From enrollment to 6 months
Change from baseline in relapse warning Signs at 1, 3, and 6 months as measured by the Advance Warning of Relapse (AWARE) Questionnaire
Timeframe: From enrollment to 6 months
Change from baseline in professional quality of life at 1, 3, and 6 months as measured by the Professional Quality of Life Scale (ProQOL)
Timeframe: From enrollment to 6 months
Post-intervention perceived feasibility of the intervention as measured by the Feasibility of Intervention Measure (FIM)
Timeframe: Immediately after the final intervention session
Post-intervention perceived acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)
Timeframe: Immediately after the final intervention session